Legal & General Group Plc Has $13.56 Million Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Legal & General Group Plc raised its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 2.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 151,550 shares of the medical equipment provider's stock after purchasing an additional 3,117 shares during the quarter. Legal & General Group Plc owned about 0.22% of Lantheus worth $13,558,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Wilmington Savings Fund Society FSB acquired a new stake in shares of Lantheus in the 3rd quarter valued at about $25,000. Kestra Investment Management LLC acquired a new stake in shares of Lantheus during the fourth quarter worth $27,000. Summit Securities Group LLC acquired a new position in Lantheus during the 4th quarter valued at approximately $37,000. UMB Bank n.a. increased its position in Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after acquiring an additional 134 shares during the period. Finally, World Investment Advisors LLC bought a new stake in Lantheus during the 3rd quarter valued at $60,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently commented on LNTH. Truist Financial boosted their target price on Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. B. Riley cut their target price on Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research report on Friday, March 21st. Finally, JMP Securities reissued a "market outperform" rating and issued a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Lantheus presently has a consensus rating of "Moderate Buy" and a consensus target price of $129.43.

Lantheus Stock Down 1.1 %

LNTH stock traded down $1.08 during trading on Monday, hitting $100.24. The company had a trading volume of 32,118 shares, compared to its average volume of 951,000. The stock has a market cap of $6.86 billion, a price-to-earnings ratio of 16.78 and a beta of 0.20. Lantheus Holdings, Inc. has a 12 month low of $62.59 and a 12 month high of $126.89. The firm has a 50-day moving average price of $95.39 and a 200-day moving average price of $95.38.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The business had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. Equities analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Insider Buying and Selling at Lantheus

In other news, Director Mary Anne Heino sold 53,107 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the sale, the director now owns 440,399 shares in the company, valued at $41,551,645.65. This represents a 10.76 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 63,109 shares of company stock valued at $6,016,046. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.